The Top 5 Biosimilars Articles for the Week of January 22
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 22, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 22.
Number 5: On the same day that its patent covering infliximab was ruled invalid, Johnson & Johnson revealed that biosimilar competition has led to a substantial drop in sales of Remicade.
Number 4: Newly published results of a survey of physicians show that some data that physicians would like to see demonstrated in bioequivalence studies may not be feasible in clinical trials.
Number 3: The European Medicines agency is asking pharmaceutical companies to report on how prepared they are for Brexit.
Number 2: A report from Trinity Partners points to complex pricing, legal and promotional issues, and a lack of biosimilar interchangeability as 3 key reasons for slow US biosimilar uptake.
Number 1: Pfizer has released positive top-line data for its proposed rituximab biosimilar in a phase 3 clinical trial.
Finally, last week, our e-newsletter asked whether biosimilars will be used in off-label indications in the same way that their reference products often are. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
